According to a report by Law360, a U.S. federal judge has denied preliminary approval of a $117 million settlement proposal between Altria Group and its shareholders regarding the company's investment in Juul Labs, stating that the proposed deal is "inadequate".
Photo: steheap. The lawsuit argues that in 2018, executives of Altria acted cautiously when they acquired a 35% stake in Juul for $12.8 billion.
According to shareholders, Altria executives are engaging in illegal and anti-competitive practices that have resulted in the loss of billions of dollars for the company. This is due to the increasing legal battles Juul is facing, as its products are suspected to pose a health risk and the company is alleged to have marketed to underage consumers. The plaintiffs argue that Altria was aware of this issue when investing, but chose to overlook it.
As Juul Labs faces increased litigation and regulatory scrutiny, the investment value of Altria has steadily declined.
The plaintiff argues for the approval of a settlement, stating that it is fair and reasonable to recover the cost and risk of further litigation. U.S. District Judge David J. Novak has not explained why he finds the settlement inadequate.
Statement:
This article is compiled from third-party information and is intended solely for industry communication and learning.
This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the truthfulness and accuracy of the article's content. The compilation of this article is only intended for industry communication and research.
Due to limitations in our translation capabilities, the translated article may not fully reflect the original text. Please refer to the original text for accuracy.
2FIRSTS maintains complete alignment with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, or foreign-related expressions or stances.
Copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us to have it removed.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
